NCT03321916已完成不适用
Controlled Pilot Study for Safety and Efficacy of Subthreshold Photothermal Therapy for Patients With Macular Telangiectasia (MacTel) Type 2
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
研究概览
简要总结
This is a two armed Single Masked Pilot Study enrolling participants with Macular Telangiectasia Type 2 who will be randomized to undergo either a subthreshold photothermal treatment or a sham procedure to one eye. The participants will be followed for one year with visits at 1 month, 3 months, 6 months and 12 months post-treatment (laser or sham). Due to the small number of participants enrolled in this study the data will be analyzed by descriptive statistics and exploratory figures. Summary statistics will be produced for study and fellow eyes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated written informed consent obtained from the participant in accordance with the local regulations;
- •Males/females 21 years of age and older but less than 80 years of age;
- •Participant must have a positive diagnosis of MacTel Type 2 in at least one eye with evidence of fluorescein leakage typical of MacTel or at least one of the other features including loss of retinal transparency/hyper-reflectivity to blue light, crystalline deposits, right angle vessels, inner/outer retinal low-reflective spaces, or hyperpigmentation not involving the center of the fovea, but no evidence of intraretinal/subretinal vascular proliferation;
- •Participant must have an Ellipsoid Zone (EZ, aka IS/OS) break in the study eye between 0.16 - 4.0 mm2 as measured on SD-OCT;
- •Participant's best-corrected visual acuity at least 55 letters (20/80) in the study eye;
- •Participant must have steady fixation in the foveal or parafoveal area of each eye, adequate pupil dilation and sufficiently clear media to perform multi-modal retinal imaging and treatment;
- •Participant must be able and willing to attend all scheduled visits.
- •For Participants undergoing optional AOSLO imaging:
- •Participant should have reproducible baseline AOSLO image montages at 2 baseline imaging sessions with quality suitable to identify a minimum of 7 regions of interest (ROIs) at which reliable cone spacing measures can be made in each eye.
排除标准
- •Participant is unable to provide informed consent;
- •Participant is less than 21 years of age or greater than 80 years of age; (but less than 80);
- •Participant is medically unable to comply with study procedures or follow-up visits;
- •Participant received intravitreal therapy for non-neovascular MacTel in the study eye and in the fellow eye, injections no sooner than 3 months prior to study treatment;
- •Participant has nystagmus in either eye;
- •Participant has greater than 7 diopters myopia in either eye;
- •Participant has been diagnosed and treated for amblyopia in the study eye;
- •Participant has significant ocular abnormalities in either eye that prevent retinal assessment, including media opacities or cataract (up to Nuclear Sclerosis +1 is allowable);
- •Participant was a study participant in any other clinical trial of an intervention (drug or device) within the last 6 months;
- •Participant has a history of malignancy that would compromise the 12 month study survival; or
- •Participant has, in the opinion of the Investigator, any physical or mental condition that would increase the patient's risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments;
- •Presence of signs of advanced retinal/vascular disease in the study eye, such as CNV, haemorrhages or macular atrophy based on OCT or FAF;
- •Previous macular laser treatment in either eye;
- •Any previous ocular condition that may be associated with a risk of developing macular oedema;
- •Vitreomacular traction determined clinically and/or by OCT, which in the opinion of the investigator contributes to the macular oedema (associated or causing a detachment of the fovea) in the study eye;
- •Presence of other macular disease such as epiretinal membrane in the study eye;
- •Ocular or periocular infections;
- •Planned intra-ocular surgery in the study eye within one year; and
- •Patient is unavailable for follow-up visits.
结局指标
主要结局
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
时间窗: 3 months post treatment
To evaluate the safety and tolerability of subthreshold photothermal therapy in patients with MacTel Type 2 as assessed by CTCAE v4.0
次要结局
- Change from baseline cone density as measured by confocal adaptive optics (AOSLO)(1 year)
- Change in size of ellipsoid zone break area as measured by spectral domain optical coherence tomography (SD-OCT)(1 year)
- Development or extension post therapy of areas of deficiency in cones as measured by AOSLO(1 year)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
AR-12286 Fixed Dose Combination to Lower Elevated Intraocular PressureGlaucomaOcular HypertensionNCT01474135Aerie Pharmaceuticals93
已完成
2 期
SYL040012, Treatment for Open Angle GlaucomaOpen Angle GlaucomaOcular HypertensionNCT02250612Sylentis, S.A.184
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back PainAcute Low Back PainNCT03424707Daewon Pharmaceutical Co., Ltd.45
已完成
不适用
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression (CSL)MyopiaNCT05724186Essilor International40
进行中（未招募）
不适用
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression.MyopiaNCT05534022Essilor International40